Brokerages predict that Heron Therapeutics Inc (NASDAQ:HRTX) will post sales of $7.98 million for the current quarter, Zacks reports. Four analysts have provided estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $9.00 million and the lowest estimate coming in at $7.00 million. Heron Therapeutics posted sales of $1.28 million during the same quarter last year, which suggests a positive year over year growth rate of 523.4%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $7.98 million for the current year, with estimates ranging from $27.00 million to $29.60 million. For the next year, analysts forecast that the firm will post sales of $60.65 million per share, with estimates ranging from $46.70 million to $83.90 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%.
Several institutional investors have recently made changes to their positions in the company. Parametric Portfolio Associates LLC lifted its stake in shares of Heron Therapeutics by 2.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 771 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Heron Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock valued at $2,363,000 after purchasing an additional 1,026 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares during the last quarter. Tudor Investment Corp ET AL lifted its stake in shares of Heron Therapeutics by 10.2% in the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 1,724 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Heron Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 2,383 shares during the last quarter.
Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.15 during trading hours on Monday, reaching $15.55. The company’s stock had a trading volume of 1,516,900 shares, compared to its average volume of 843,120. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $18.40.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/18/7-98-million-in-sales-expected-for-heron-therapeutics-inc-hrtx-this-quarter.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.